Annovis Bio Inc
Veridion Score
Composite trend over time
Why is ANVS moving today?
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for ANVS.
ANVS insider activity
Annovis Bio Inc
No multi-insider buying cluster in the last 90 days
Net buying: $4.6M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | 2026-05-20 | Hoffman Michael B | Insider | buy | $1.90 | 54,933 | 3,364,883 | $104K | SEC Form 4 |
| 2026-05-21 | 2026-05-20 | Hoffman Michael B | Insider | buy | $1.80 | 18,849 | 3,309,950 | $34K | SEC Form 4 |
| 2026-05-21 | 2026-05-20 | Hoffman Michael B | Insider | buy | $1.75 | 2,562 | 3,291,101 | $4K | SEC Form 4 |
| 2026-04-03 | 2026-04-02 | Hoffman Michael B | Insider | buy | $2.10 | 713,800 | 3,288,539 | $1.5M | SEC Form 4 |
| 2025-12-08 | 2025-12-08 | Hoffman Michael B | Insider | buy | $4.24 | 15,000 | 2,574,739 | $64K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 25 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moANVS contract awards, year to date.
Public federal awards linked to this ticker.
ANVS lobbying filings, year to date.
Registered lobbying filings matched to Annovis Bio Inc.